BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Genta Incorporated (OTCBB: GNTA) announced the presentation of a progress update from the Company’s ongoing Phase 3 trial of Genasense® (oblimersen sodium) Injection, Genta’s lead oncology product, in patients with advanced melanoma. A pooled analysis of data from this study, which remains blinded, was compared with the Company’s previous data from a similarly designed randomized trial. The comparative analysis shows that to date AGENDA has enrolled patients with similar demographics, and also that the aggregate incidence of serious adverse events is comparable. The data were presented this past weekend by Dr. Agop Bedikian at an international symposium entitled Perspectives in Melanoma XII in The Hague, The Netherlands.
